Canaan XI L.P.'s Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Sep 22, 2022
- Accession no.
- 0000899243-22-031692
- Filed
- Sep 22, 2022, 4:00 PM ET
- Trade date
- Sep 21, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $11.4M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Canaan XI L.P.CIK 0001712417 | 10% Owner |
| Canaan Partners XI LLCCIK 0001850694 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2022 | Common Stock | SSaleDisposed | −607,497 | $18.54F1 | −$11,262,994.38 | 8,470,407 | Direct | Duplicate filing |
| Sep 21, 2022 | Common Stock | SSaleDisposed | −6,106 | $19.29F3 | −$117,784.74 | 8,464,301 | Direct | Duplicate filing |
| Sep 21, 2022 | Common Stock | JOtherDisposed | −1,500,000 | –F4 | – | 6,964,301 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
Referenced by the price of 1 transaction in Table I.